Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Immunity, Mucosal”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,477 records · Page 82Linked to original sources

Therapeutic approaches to chronic intestinal inflammation by specific targeting of mucosal IL-7/IL-7R signal pathway.

Inflammatory bowel disease is thought to result from inappropriate activation of mucosal immune responses. Intestinal epithelial cells produce interleukin (IL)-7 that serves as a regulatory factor for IL-7 receptor (IL-7R)(+) mucosal lymphocytes. The pivotal role of mucosal IL-7/IL-7R dependent signals in the activation of mucosal immune responses that lead to the development of chronic intestinal inflammation are demonstrated. Therapeutic approaches targeting IL-7/IL-7R signal pathway may be feasible in the treatment of inflammatory bowel disease.

Animals↗

Developments in mucosal influenza virus vaccines.

Immunogenicity and efficacy of aerosol inactivated split influenza virus vaccines, which are threefold the strength of the vaccines for parenteral use, and cold-adapted reassortant live influenza virus vaccines were evaluated. Mucosal immune responses were evaluated by quantifying specific IgA antibody of the nasal swab solution, and systemic immune responses were evaluated by determining serum haemagglutination inhibition antibody levels. Efficacy of the aerosol inactivated vaccine was evaluated by a challenge test using live vaccine virus. It was concluded that mucosally administered inactivated influenza virus vaccine stimulated systemic and mucosal immune responses more strongly than live influenza virus vaccine and manifested a much stronger booster effect than live vaccine. Mucosal administration of inactivated influenza virus vaccine was effective in preventing infection by live vaccine virus.

Administration, Intranasal↗

Influence of microparticle formulation on immunogenicity of SYI, a synthetic peptide derived from Streptococcus mutans GbpB.

Subcutaneous immunization with SYI, a peptide construct based on Streptococcus mutans glucan binding protein B (GbpB) residues 113-132, significantly reduces experimental dental caries. Since mucosal immunization may be preferred for human vaccine applications, the present objective was to determine what formulation of SYI combined with polylactide-coglycolide microparticles could give rise to significant levels of salivary IgA antibody reactive with the native GbpB protein. A comparison of the SYI construct, loaded into or mixed with polylactide-coglycolide revealed the SYI-loaded microparticles to induce significant and sustainable levels of salivary and nasal wash IgA antibody to the peptide and the native protein. SYI mixed with unloaded microparticles was less effective in mucosal antibody response induction. These studies indicate that mucosal immunization with the SYI construct can induce salivary IgA antibody to a pathogenesis-associated component of S. mutans if delivered within polylactide-coglycolide microparticles, suggesting that this approach could successfully induce protective salivary immunity to dental caries caused by S. mutans.

Animals↗

A comparative study of the characteristics of intraepithelial and lamina propria lymphocytes of the human nasal mucosa.

The phenotypes and receptors of the intraepithelial lymphocytes which are a major component of the mucosal immune system are of considerable interest. Intraepithelial lymphocytes, especially those of the intestines, are well documented. The nasal intraepithelial lymphocytes probably play a key role in the immune defense of the entire respiratory tract. However, documentation of these lymphocytes is limited to only a few nondescriptive studies by immunohistological methods. In our previous paper, we examined the subsets of the nasal intraepithelial lymphocytes by two-color flow cytometry after culture with monoclonal antibody against CD3 and PMA. The mucosal immune system, which comprises the lymphoid tissue associated with the mucosal surface, consists of lymphocyte populations from both the epithelium and the lamina propria. In this paper (a sequel to our previous study), we have carried out a comparative study of the intraepithelial lymphocytes and lamina propria lymphocytes of the human nasal mucosa. In the 42 patients (with allergic rhinitis/infectious hypertrophic rhinitis) whom we examined, T lymphocytes were predominant in the epithelium as well as the lamina propria. B lymphocytes were detected only in the lamina propria. CD8+ T cells (suppressor/cytotoxic) and CD4-8- (double-negative) (DN) comprised the major population of the intraepithelial lymphocytes. The CD4+/CD8+ ratio was 0.5 +/- 0.1. In contrast, the lamina propria showed a predominance of CD4+ T cells (helper/inducer), with a CD4+/CD8+ ratio of 1.3 +/- 0.2. CD3 + 4-8- (double-negative T cells) were comparable in number in the epithelium and the lamina propria. CD8+ T cells of the epithelium were predominantly cytotoxic T cells, and CD4+ T cells were predominantly helper T cells. In the lamina propria, CD8+ T cells were predominantly of the suppressor type.(ABSTRACT TRUNCATED AT 250 WORDS)

Adolescent↗

Bovine lactoferrin induces both mucosal and systemic immune response in mice.

Lactoferrin (Lf) is a milk iron-binding glycoprotein that plays a role in iron transport and acts as both a bacteriostatic and a growth modulating agent. The aim of this study was to investigate the nature of immune responses induced by repeated oral administration of bovine milk Lf in mice. Groups of ten female BALB/c mice were fed daily for 4 weeks with two doses of protein antigen: a low (0.05 mg/g body weight per d) or high (1 mg/g body weight per d) dose of Lf, or water as a control. A fourth group was immunized intramuscularly with 0.01 mg Lf in complete Freund's adjuvant. Anti-Lf IgA and IgG were detected in the intestinal fluid and serum of mice given Lf. Total immunoglobulins were higher in the intestinal fluid in Lf groups than in the control group. No difference could be detected in the serum. IgA and IgG secretion was enhanced in Peyer's patches and spleen from Lf-fed mice, in comparison with controls. [3H]thymidine uptake into Peyer's patch and spleen cells from both control and Lf-fed mice was enhanced by 75 micrograms Lf/ml in vitro, but Lf groups had a greater proliferation rate than the control group. These findings suggested that Lf could act as an immunostimulating factor on the mucosal immune system and that activation of the mucosal immune system is dependent on the ability of Lf to bind to the intestinal mucosa.

Administration, Oral↗

Immunization of BALB/c mice with Helicobacter urease B induces a T helper 2 response absent in Helicobacter infection.

BACKGROUND & AIMS: Infection with Helicobacter induces a T helper type 1 response in mice and humans. Mice can be cured or protected from infection with Helicobacter by mucosal immunization with recombinant H. pylori urease B subunit (rUreB). This study characterizes the immune response of infected mice immunized with rUreB. METHODS: BALB/c mice were infected with H. felis. Two weeks later, they were orally immunized four times with rUreB and cholera toxin (CT) at weekly intervals. Controls were only infected or sham-immunized with CT. Animals were killed at various times after immunization. Splenic CD4(+) cells were obtained and cultured in vitro with rUreB to evaluate antigen-specific proliferation and induction of interferon gamma and interleukin 4 secretion. RESULTS: All rUreB-immunized mice (n = 8) were cured from infection 3 weeks after the fourth immunization. Immunization induced a proliferative response of splenic CD4(+) cells, a progressive decrease in interferon gamma secretion, and a concomitant increase in interleukin 4 secretion after each immunization. A simultaneous increase in rUreB specific serum immunoglobulin G1 levels was observed in infected/immunized mice. CONCLUSIONS: In BALB/c mice, therapeutic mucosal immunization with rUreB induces progressively a Th2 CD4(+) T cell response resulting in the elimination of the pathogen.

Animals↗

Mucosal and systemic immunity to bovine herpesvirus-1 glycoprotein D confer resistance to viral replication and latency in cattle.

Mucosal immunity in the respiratory tract directed against bovine herpesvirus-1 (BHV-1) glycoprotein B forms an effective barrier against BHV-1 replication in cattle. Here we investigated the ability of a second BHV-1 glycoprotein, gD, to engender specific antibodies in nasal secretion and serum and protect against infection. We expected gD to give greater protection than gB because anti-gD antibodies prevent viral penetration into cells at much lower concentrations than anti-gB antibodies. Calves vaccinated once subcutaneously and thrice intranasally with affinity-purified BHV-1 gD had mucosal antibodies and three of five were protected against intranasal challenge by 10(7) p.f.u. of BHV-1. Four of the five vaccinated calves were proven free of BHV-1 latency by the lack of viral shedding following immunosuppression. The putative mucosal adjuvant, cholera toxin B subunit (CTB), did not significantly enhance mucosal immunity or protection against challenge or latency (P0.5) since only 4 of 6 gD plus CTB immunized calves were completely protected. Taken together, these data suggest that BHV-1 gD may be useful in a mucosal vaccine against BHV-1 infection in cattle but is less than totally effective when used alone.

Animals↗

Impaired host immunity contributes to Helicobacter pylori eradication failure.

OBJECTIVES: Effective eradication of Helicobacter pylori (H. pylori) infection has often proved more difficult than expected. Antimicrobial resistance incompletely explains eradication failure. This study tests the hypothesis that an impaired immune response may contribute to failed eradication after standard antibiotic therapy. METHODS: Parameters of host immunity were assessed as blood T lymphocyte production of interferon-gamma (IFN-gamma) and interleukin-4 (IL-4) being surrogate markers of mucosal Th1 and Th2 responses, respectively. The validity of using circulating T cell cytokines as surrogate markers of mucosal immunity was established (unstimulated lymphocyte IL-4 level correlation r2 = 0.549, p < 0.001; antigen-stimulated lymphocyte correlation r2 = 0.62, p < 0.001). RESULTS: A total of 52 dyspeptic patients and 11 patients with previous H. pylori eradication failure were recruited into the study. There was no significant difference in secretion of IFN-gamma from peripheral blood T cells, in either unstimulated or antigen-stimulated cultures, between clinical groups. There was, however, a significant reduction in secretion of IL-4 from blood T cells in subjects failing to eradicate H. pylori compared with those who successfully eradicated the infection in both unstimulated and stimulated cultures. A significant difference in IL-4 secretion was also detected in antigen-stimulated cultures compared with that in H. pylori-positive subjects (p < 0.05). Low levels of IL-4 secretion were detected irrespective of the number of courses of antibiotic therapy. Lower levels of IgG anti-H. pylori antibody were detected in both serum and saliva of subjects with persistent H. pylori infection after use of antibiotics compared with untreated H. pylori-positive subjects (difference not statistically significant). CONCLUSIONS: These results support the hypothesis that impaired mucosal immunity, particularly involving the secretion of IL-4, may contribute to H. pylori eradication failure. Measurement of whole blood secretion of IL-4 may predict which patients are more likely to fail standard antibiotic therapy.

Blood↗

Active immunity is seen as a reduction in the cell response to oral live vaccine.

Oral immunization elicits a response of antibody-secreting cells (ASC) in the peripheral blood; these cells are believed to originate in the mucosa and hence give information on the mucosal immune response. We have shown earlier that oral booster immunization is followed by an elevated ASC response reflecting an immunologic memory. In the present study we show that a booster dose of a live bacterial vaccine given at a time of active mucosal immunity elicits a low ASC response only. This is probably because the multiplication of the live vaccine is inhibited in the gut, resulting in a low actual dose of the antigen. This situation may be an example of the protective immunity manifested when an orally immunized person encounters the pathogen in nature, and could be used to assess the protective immunity.

Administration, Oral↗

Overview of new vaccines and technologies.

Molecular technology has given us a greater insight into the aetiology of disease, the functioning of the immune system and the mode of action of veterinary pathogens. The knowledge gained has been used to develop new vaccines with specific, reactive antigens which elicit protective immune mediated responses (humoral and/or cell mediated) in the host. These vaccines should not burden the immune system by initiating responses against non-essential antigens. However, the efficacy of these vaccines is only as good as the delivery technology or route used to present them to the immune system. Some vaccines, traditionally given by the parenteral route, are now given by the natural route; either orally or intranasally. Two major advantages, often interrelated, are the rapid onset of immunity and stimulation of the local, mucosal immunity. These new technologies are now making an impact on current vaccine development. The balance has to be found between what is technologically feasible and what will provide at least as good a protective immunity as current, conventional vaccines. As new and emerging diseases appear globally, new opportunities arise for molecular and conventional technologies to be applied to both the development and delivery of novel vaccines, as well as the improvement of vaccines in current use.

Animals↗

The cellular basis of immune induction at mucosal surfaces by DNA vaccination.

The nasal mucosa provides a simple, non-invasive route to deliver DNA encoding the gene of interest to stimulate mucosal and systemic immune responses. However, unlike the intradermal or intramuscular routes for plasmid DNA (pDNA) delivery, immune responsiveness to antigen exposure at the respiratory mucosa is tightly regulated, consistent with the balance between active immunity and non-responsiveness to pathogenic or inert environmental antigens. We have characterised the antigen presenting cell types, their distribution and activation status following nasal vaccination with pDNA-cytofectin complexes encoding model antigens. We demonstrate that nasal immunisation is associated with expression of the encoded protein in a small population of dendritic cells and macrophages at the site of pDNA delivery, in the draining lymph nodes (LN) and in the spleen. Antigen expression by nasal dendritic cells was associated with up-regulation of surface MHC class II and CD86 expression and functional activation of T-lymphocytes. The results highlight the potential of intranasal vaccination with pDNA, provided the activation / costimulatory requirements for an active immune response are achieved.

Administration, Intranasal↗

Cellular and molecular immunopathogenesis of ulcerative colitis.

Ulcerative colitis (UC) is an inflammatory disease of the rectal and colonic mucosa and seems to result from a complex series of interactions between susceptibility genes, the environment and the immune system. Various components of the mucosal immune system are implicated in the immunopathogenesis of UC. Evidence from animal models also suggests that an altered immune response to the commensal microflora of the host plays a central role in the development of UC. So in this review, we elucidate the cells and molecules which are implicated in the immunopathogenesis of the disease from four aspects: antigens in the intestine, dendritic cells, toll like receptors and NF-kappaB in the UC.

Animals↗

[Secretory immunity of the airways].

INTRODUCTION: Continuous exposure of the respiratory tract to inhaled particles and microbes implies the presence of effective defence mechanisms at a bronchial and alveolar level. STATE OF ART: Among the mechanisms involved secretory mucosal immunity contributes considerably to the defence of the bronchial tree. This immunity depends essentially on the active trans-epithelial transport of IgA involved in both innate non-specific and acquired specific immunity. Recently an IgA receptor has been identified on the surface of phagocytes including alveolar macrophages, establishing a link between alveolar and bronchial defences. PERSPECTIVES: The respiratory mucosa represents a crucial interface between the host and its environment, and should provide in the future a new target for the development of diagnostic and therapeutic tools. CONCLUSIONS: Beyond its function as an anatomical barrier the bronchial epithelium possesses a secretory activity that is essential for the protection of the lung. Despite a better understanding of mucosal immunity this secretory activity and in particular the part played by IgA remains to be elucidated.

Antigens, CD↗

Mucosal IgA response to rectally administered antigen formulated in IgA-coated liposomes.

Ferritin, a soluble model antigen, was used to test whether liposomes can provide an effective delivery vehicle for mucosal immunization via the rectum, and whether the local colonic/rectal secretory immune response to antigen in liposomes can be enhanced by immunoadjuvants. The colonic/rectal IgA response to liposomal ferritin was significantly enhanced over the response to free ferritin but only when cholera toxin (CT) was present as adjuvant. The presence of IgA on the liposome surface increased the uptake of liposomes into Peyer's patch mucosa, and the local rectal/colonic immune response to ferritin about 5-fold over uncoated liposomes. These results show that (1) liposomes co-administered with immunoadjuvants can be used for mucosal immunization via the rectum. (2) Cholera toxin is an effective immunoadjuvant in the rectal/colonic mucosa. (3) IgA can enhance the local secretory immune response to antigen in liposomes, apparently by increasing liposome uptake via M cells.

Adjuvants, Immunologic↗

Drug induced lymphocytic colitis.

Three cases are presented of lymphocytic colitis with chronic diarrhoea concurrent with longterm use of Cyclo 3 Fort, a phlebotonic drug used in France. The histological and immunopathological features of lymphocytic colitis are described. We show that lymphocytic colitis is drug induced, particularly in one patient where the immunopathological features of mucosal immune cell activation were induced by drug rechallenge. It is concluded that lymphocytic colitis may be drug induced, secondary to a chronic activation of the mucosal immune system by one or several components of the drug.

Aged↗

Identification of an immunodominant T cell epitope on cholera toxin.

Cholera toxin (CT), the enterotoxin of Vibrio cholerae, is a potent mucosal immunogen as well as a strong mucosal adjuvant to related and unrelated antigens. The mucosal immune response to CT is T cell dependent and MHC class II restricted. The epitopes on CT recognized by T cells have not been identified. The purpose of this study was to determine the fine specificity of T cell recognition of both the CT A subunit (CT-A) and the CT B subunit (CT-B) by using a range of synthetic peptides. After immunization with CT-B or CT-A in CFA subcutaneously, the peripheral lymph node T cells were stimulated with different synthetic peptides in vitro. The peptide specificity of T cell recognition was identified by assaying T cell proliferation and interleukin-3 production. T cells from C57BL/6 (H-2b) high responder mice recognized one immunodominant epitope (peptide 89-100) and one weak epitope (peptide 31-50) on CT-B and two epitopes (peptide 21-39 and 180-194) on CT-A. The immunization of C57BL/6 mice with synthetic immunodominant CT-B peptide 89-100 induced T cell immunity to the pentameric CT-B. Induction of tolerance to CTB peptide 89-100 by i.v. injection in high responder C57BL/6 mice induced unresponsiveness to mucosal immunization with CT, compatible with an immunodominant role for this T cell epitope.

Amino Acid Sequence↗

Distribution of monoclonal antibodies in intestinal and urogenital secretions of mice bearing hybridoma 'backpack' tumours.

Mice bearing IgA hybridoma 'backpack' tumours have been used to demonstrate that secretion of a single monoclonal IgA can protect against mucosal infection, but the relevance of this model to normal IgA protection is not clear. The authors analysed the distribution of specific monoclonal and total antibodies in bile, local intestinal secretions, cervical-vaginal secretions, urine and serum of mice bearing anti-cholera toxin (CT) IgA and IgG backpack tumours, with and without bile duct ligation. Backpack tumours resulted in high levels of both anti-CT and total IgA or IgG in serum, and IgA (but not IgG) in bile. Secretions recovered by absorbent filter 'wicks' from mucosal surfaces throughout the intestines of backpack tumour mice contained significant concentrations of monoclonal anti-CT IgA, but total IgA levels were as in normal mice. Neither monoclonal nor total IgA levels on mucosal surfaces were altered by bile duct ligation. Furthermore, anti-CT monoclonal IgA levels in local intestinal secretions of backpack tumour mice were comparable to specific polyclonal IgA levels previously elicited by mucosal immunization with CT. Thus, IgA-mediated protection against enteric challenge in the backpack tumour model may be a valid predictor of protection provided by natural mucosal immunization in vivo. High monoclonal IgA levels in bile, urine and the female genital tract, however, may not reflect the situation in normal immunized mice.

Animals↗

Influenza virus infection of the murine uterus: a new model for antiviral immunity in the female reproductive tract.

Secretory IgA (S-IgA) mediates local immunity to influenza virus in the murine upper respiratory tract and may play an important role in local immunity to various microorganisms in the female reproductive tract as well. Although the presence of IgA in cervicovaginal or uterine secretions has been correlated with immunity to a number of pathogens, there has been no direct demonstration of the mediation of uterine antiviral immunity by S-IgA. Influenza virus, although not a normal pathogen of the reproductive tract, was used to develop a model for the investigation of mucosal immunity in the uterus. PR8 (H1N1) influenza virus injected into the ovarian bursa of BALB/c mice grew well, with peak titers between days 3 and 5. Intravenous injection of polymeric IgA anti-influenza virus monoclonal antibody before or 30 min after viral challenge protected mice against viral infection. We believe this work to be the first direct demonstration of S-IgA-mediated antiviral uterine immunity. It provides a model for further investigation of immunity in the female reproductive tract.

Animals↗